Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2022-04-22 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2021年度监事会工作报告" which translates to "2021 Supervisory Board Work Report". It details the supervisory board's activities, oversight of company operations, financial status, compliance with laws, and internal controls for the year 2021. It includes summaries of meetings, resolutions, and opinions on company operations and financials, but does not contain full financial statements or detailed financial data itself. The document is a report from the supervisory board on their work and oversight, not an annual report or audit report. It is not a short announcement or certification but a substantive report on supervisory activities. This fits best under the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports on company governance and oversight.
2022-04-22 Chinese
公司章程(2022年4月）
Governance Information Classification · 100% confidence The document is titled '章程' which translates to 'Articles of Association' or 'Company Bylaws'. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. It references Chinese company law and securities law, and includes detailed chapters on shareholder meetings, board of directors, management, financial accounting, and amendments to the articles. There is no indication that this is a financial report, earnings release, or any announcement of voting results or capital changes. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not just an announcement or summary.
2022-04-22 Chinese
2021年非经营性资金占用及其他关联方资金往来情况的专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) concerning non-operating fund occupation and other related party fund transactions for the year 2021. It references an audit report issued on April 22, 2022, and includes detailed tables summarizing related party transactions and fund balances. The document is focused on compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding related party transactions and fund usage. It is not a full annual report (10-K), nor an earnings release or management discussion. It is a standalone audit-related special report on a specific topic (non-operating fund occupation and related party transactions), which fits the definition of an Audit Report / Information (AR). The document length (6233 characters) and detailed financial data support it being a substantive report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2021
2022-04-22 Chinese
2021年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2021年度财务决算报告 (2021 Annual Financial Settlement Report) of 美康生物科技股份有限公司. It contains detailed financial data for the year 2021, including audited financial statements, income, profit, cash flow analysis, and asset/liability breakdowns. The audit report is mentioned as issued by an accounting firm, confirming the financial statements' compliance and fairness. The document covers the full fiscal year 2021 and includes comprehensive financial performance and position information. It is not a brief announcement or a certification letter but a full financial report. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-04-22 Chinese
2021年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021 年度董事会工作报告" which translates to "2021 Annual Board of Directors Work Report". It contains a detailed review of the company's 2021 business performance, board meeting summaries, execution of shareholder resolutions, committee operations, independent directors' duties, investor relations, information disclosure, and plans for 2022. The content focuses on the board's activities and governance rather than full financial statements or audit opinions. It is a comprehensive report on board and management activities rather than an annual report (10-K) or audit report (AR). The document length is 7040 characters, which is substantial and contains detailed board-related information. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-04-22 Chinese
股东大会议事规则(2022年4月）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则（2022年4月）" which translates to "Shareholders' Meeting Rules (April 2022)". It details the rules and procedures for convening and conducting shareholders' meetings, including the powers of the shareholders' meeting, the process for calling meetings, voting procedures, and regulatory compliance. It does not contain financial statements, audit opinions, or earnings data. It is a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is substantial and it is not an announcement or a brief notice, so it is not an RPA or RNS. Hence, the classification is CGR with high confidence.
2022-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.